Findings from DEVOTE support clinical benefits of the high-dose regimen of nusinersen (50 mg and 28 mg) in both ...

A trial found that off-the-shelf TRX103 Tr1 cells were safe to use after mismatched donor stem cell transplant, showing engraftment and dose-dependent expansion and persistence.

If approved, marstacimab would be the first non-factor prophylactic treatment indicated for pediatric patients aged 6 to 11 years with hemophilia B.

Dr James Chambers discusses handling a patient enquiry about inclisiran, including how to explain current evidence for its ...

Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular”), an integrated biopharmaceutical company committed to redefining the retina ...

Amlitelimab is effective at improving moderate to severe AD across all body regions, including the difficult-to-treat head and neck region.

FDA priority review seeks marstacimab label expansion to ≥6 years with inhibitors and ages 6–11 without inhibitors, addressing populations with limited efficacy from factor replacement and high unmet ...

Investigational antiviral pritelivir demonstrates efficacy and improved tolerability over current treatments for refractory HSV in high-risk patients.

Grip strength exercises after 60 to restore hand power fast, from a certified trainer. Learn the 4 moves.

Pritelivir met its primary endpoint of superior lesion healing, achieving a 62.7% lesion healing rate compared to 34.0% with standard-of-care therapies (investigator’s choice), resulting in an ...

Herbs have been used as medicine for thousands of years, and even today, they can still play a part alongside conventional ...

1) the active drug substance Axitinib, which used to belong to Pfizer, is an FDA-approved, oral, potent VEGFR inhibitor. So ...